x

Posted 09 September, 2022

Adhera Therapeutics, Inc. appointed Zahed Subhan as new CEO

OTC:ATRX appointed new Chief Executive Officer Zahed Subhan in a 8-K filed on 09 September, 2022.


  On September 8, 2022, the Board of Directors (the "Board") of Adhera Therapeutics, Inc. (the "Company") appointed Zahed Subhan as the Company's Chief Executive Officer and Andrew Kucharchuk as the Company's Chief Operating Officer, effective September 30, 2022.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Adhera Therapeutics, Inc.
Health Care/Life Sciences • Biotechnology
Adhera Therapeutics, Inc. is an emerging specialty biotech company, which is in the process of evaluating its focus including a return to drug discovery and development. The company was founded on September 23, 1983 and is headquartered in Baton Rouge, LA.
Market Cap
$103K
View Company Details
Adhera Therapeutics, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On September 8, 2022, the Board of Directors (the "Board") of Adhera Therapeutics, Inc. (the "Company") appointed Zahed Subhan as the Company's Chief Executive Officer and Andrew Kucharchuk as the Company's Chief Operating Officer, effective September 30, 2022. Mr. Kucharchuk will continue to serve as the Company's Chief Executive Officer until September 30, 2022. 


Mr. Subhan, 64, has been serving as the Company's director since November 5, 2021. He has served as the Chief Executive Officer and director of Aestas Pharma Inc. since 2015. Mr. Subhan has also been a director of Eppin Pharma Inc. ("Eppin") since 2013, and the Chief Executive Officer of Eppin from 2013 to 2018.


Mr. Kucharchuk, 41, has served as the Chariman of our Board and Chief Executive Officer since July 7, 2020. He has also served on the Board of Directors of Theralink Technologies, Inc. ("Theralink") since 2020 after previously serving in such role from September 2015 to March 2017. Previously, he served as President and Chief Financial Officer of Theralink from February 2016 until June 2020, as Chief Executive Officer of Theralink from November 2019 until June 2020, and as Chief Financial Officer of Theralink from 2009 to September 2015. Mr. Kucharchuk has also served as Acting Chief Financial Officer of Theralink from June 2020 to September 2020.